SAB Biotherapeutics (SABS) Interest Expenses (2020 - 2026)
SAB Biotherapeutics (SABS) posted Interest Expenses of $27.6 million for Q1 2026, up 5633.72% on a QoQ basis from -$497968.0 in Q4 2025, and up 10453.66% year-over-year from N/an in Q1 2025.
SAB Biotherapeutics (SABS) Interest Expenses (2020 - 2026) Analysis & Trends
SAB Biotherapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $27.6 million for Q1 2026.
- Quarterly Interest Expenses rose 10453.66% year-over-year to $27.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.6 million (up 10453.66% YoY) and the FY2025 annual result came in at $26.1 million, up 2098.01% from the prior year.
- Interest Expenses was $27.6 million for Q1 2026 at SAB Biotherapeutics, up from -$497968.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $27.6 million in Q1 2026 and bottomed at -$497968.0 in Q4 2025.
- A 5-year average of $2.1 million and a median of $311000.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2025 — Interest Expenses slumped 489.04% — and 2026, when it soared 10453.66%.
- SAB Biotherapeutics' Interest Expenses stood at $1.1 million in 2022, then tumbled by 103.66% to -$38716.0 in 2023, then surged by 430.61% to $128000.0 in 2024, then slumped by 489.04% to -$497968.0 in 2025, then jumped by 5633.72% to $27.6 million in 2026.
- Business Quant data shows SABS's Interest Expenses at $27.6 million in Q1 2026, -$497968.0 in Q4 2025, and $728650.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | SAB Biotherapeutics | 187.72 Mn | 187.72 Mn | - | 27.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.56 Mn |
| Mar 31, 2026 | 27.56 Mn |
| Dec 31, 2025 | -497,968.00 |
| Dec 31, 2025 | -497,968.00 |
| Sep 30, 2025 | 728,650.00 |
| Sep 30, 2025 | 728,650.00 |
| Jun 30, 2025 | 728,650.00 |
| Jun 30, 2025 | 728,650.00 |
| Mar 31, 2025 | 261,105.00 |
| Mar 31, 2025 | 261,105.00 |
| Dec 31, 2024 | 128,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | 261,000.00 |
| Sep 30, 2024 | 261,000.00 |
| Jun 30, 2024 | 246,000.00 |
| Jun 30, 2024 | 246,000.00 |
| Mar 31, 2024 | 236,105.00 |
| Mar 31, 2024 | 236,105.00 |
| Dec 31, 2023 | -38,716.00 |
| Dec 31, 2023 | -38,716.00 |